The deal, terms of which were not disclosed, will see the Indian contract research organisation's (CRO) 100-strong staff provide early-clinical trial and bioanalysis services to both local and multinational developers at its 92-bed research unit in Hyderabad under the QPS-Bioserve India.
QPS CEO Ben Chien said: “With access to Bioserve's additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400; greater bioanalytical capacity and access to another facility.”
QPS, which offers a range of preclinical and clinical drug development services, is continuing with the growth through acquisition strategy which, last year, saw it but Netherlands-based Xendo Drug Development (XDD) to expand its European business.
QPS joins Quintiles as the second western CRO to expand its Phase I trial offering in India this week.